All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.
The aml Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the aml Hub cannot guarantee the accuracy of translated content. The aml and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The AML Hub is an independent medical education platform, sponsored by Daiichi Sankyo, Johnson & Johnson, and Syndax, and has been supported through an educational grant from the Hippocrate Conference Institute, an association of the Servier Group. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out moreCreate an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View aml content recommended for you
Acute Myeloid Leukemia (AML) driven by translocations involving Mixed-Lineage Leukemia (MLL) is an aggressive subtype characterized by poor prognosis. There is a need for new therapeutic agents to treat these aggressive AML subtypes, hence the rationale for this study.
Nadine Hein, from The John Curtin School of Medicine, and colleagues investigated the therapeutic efficacy and mechanism of CX-5461, a novel inhibitor of RNA Polymerase I (Pol I), in AML driven by MLL fusion proteins. The results of the study were published ahead of print in Blood on 10 March 2017.
In summation, CX-5461 mediated inhibition of Pol 1 can treat aggressive AML effectively compared to standard chemotherapy. Moreover, CX-5461 induced p53-independent cell cycle and decreased the frequency of LICs. Additionally, the authors suggested that inhibition of Pol I “may represent a promising new approach to treat human AML by targeting the LIC independent of functional p53”.
The authors concluded by stating that their results demonstrate that CX-5461 can effectively treat aggressive hematological malignancies. Furthermore, inhibition of Pol I transcription may be broadly beneficial in a variety of hematological malignancies with TP53 mutations. Based on this preclinical data, a phase I open-label study (12613001061729, Australian New Zealand Clinical Trials Registry) is currently underway. In this study, the maximum tolerated dose of CX-5461 is being evaluated in patients with advanced hematological malignancies including relapsed or refractory AML.
Despite the development of novel drugs, prospects for many patients with acute myeloid leukemia (AML) remain dismal. This study reveals that the selective inhibitor of RNA Polymerase I (Pol I) transcription, CX-5461, effectively treats aggressive AML, including MLL-driven AML, and outperforms standard chemotherapies. In addition to the previously characterized mechanism of action of CX-5461, the induction of p53-dependant apoptotic cell death, inhibition of Pol I transcription also demonstrates potent efficacy in p53null AML in vivo. This significant survival advantage in both p53WT and p53null leukemic mice treated with CX-5461 is associated with activation of the checkpoint kinases CHK1/CHK2, an aberrant G2/M cell cycle progression and induction of myeloid differentiation of the leukemic blasts. The ability to target the leukemic-initiating cell population is thought to be essential for lasting therapeutic benefit. Most strikingly, acute inhibition of Pol I transcription reduces both the leukemic granulocyte-macrophage progenitor and leukemia initiating cell (LIC) populations, and suppresses their clonogenic capacity. This suggests that dysregulated Pol I transcription is essential for the maintenance of their leukemia initiating potential. Together these findings demonstrate the therapeutic utility of this new class of inhibitors to treat highly aggressive AML by targeting leukemia initiating cells.
References